Related references
Note: Only part of the references are listed.Assessment of Availability, Clinical Testing, and US Food and Drug Administration Review of Biosimilar Biologic Products
Thomas J. Moore et al.
JAMA INTERNAL MEDICINE (2021)
The Path Towards a Tailored Clinical Biosimilar Development
Martin Schiestl et al.
BIODRUGS (2020)
British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update
C. H. Smith et al.
BRITISH JOURNAL OF DERMATOLOGY (2020)
Adalimumab Biosimilars in Europe: An Overview of the Clinical Evidence
Salvatore Bellinvia et al.
BIODRUGS (2019)
The arrival of biosimilar monoclonal antibodies in oncology: clinical studies for trastuzumab biosimilars
Liese Barbier et al.
BRITISH JOURNAL OF CANCER (2019)
Evolution of the EU Biosimilar Framework: Past and Future
Elena Wolff-Holz et al.
BIODRUGS (2019)
Biosimilars vs originators: Are they the same?
Piercarlo Sarzi-Puttini et al.
AUTOIMMUNITY REVIEWS (2019)
Etanercept biosimilar SB-4
Eleftherios Pelechas et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2019)
Biosimilars in the USA: Will New Efforts to Spur Approvals and Access Spur Uptake and Cost Savings?
Stanton R. Mehr et al.
PHARMACEUTICAL MEDICINE (2019)
Biosimilars: A consideration of the regulations in the United States and European union
Justin Daller
REGULATORY TOXICOLOGY AND PHARMACOLOGY (2016)
On the Regulatory Approval Pathway of Biosimilar Products
Jun Wang et al.
PHARMACEUTICALS (2012)
Share Paper
